Regeneron price target raised to $460 from $350 at Canaccord Canaccord raised its price target on Regeneron to $460 from $350 to reflect the upside potential of Eylea in Diabetic Macular Edema which was approved by the FDA in July. The firm also noted the sales pace of Lucentis only slowed slightly. Canaccord reiterated its Buy rating on Regeneron shares
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.